What is the appropriate diagnostic work‑up and treatment plan for a patient suspected of systemic lupus erythematosus (SLE)?

Diagnostic Work-Up and Treatment of Systemic Lupus Erythematosus

Diagnostic Approach

Begin with ANA testing as the mandatory entry criterion—a positive ANA at titer ≥1:80 by indirect immunofluorescence on HEp-2 cells is required before proceeding with further SLE evaluation. 1

Initial Serologic Testing

• Order ANA first in any patient with unexplained involvement of two or more organ systems (e.g., rash plus arthritis, fever plus cytopenias, serositis plus renal abnormalities). 1
• If ANA is negative and clinical suspicion persists, repeat testing in 3–6 months. 1
• Once ANA is positive, proceed with anti-dsDNA antibodies using both a sensitive method (solid phase assay) and a specific method (Crithidia luciliae immunofluorescence test) to optimize diagnostic accuracy. 2, 1
• Test for anti-ENA antibodies: anti-Smith (highly specific for SLE), anti-Ro/SSA, anti-La/SSB, and anti-U1-RNP. 1
• Measure complement levels (C3, C4, CH50)—low levels indicate active disease and correlate with lupus nephritis. 2, 1

Baseline Laboratory Evaluation

• Complete blood count to detect cytopenias: leukopenia (<4,000/mm³), lymphopenia (<1,000/mm³), thrombocytopenia (<100,000/mm³), or hemolytic anemia. 2, 1
• Serum creatinine and eGFR to assess renal function. 2, 1
• Urinalysis with microscopy and urine protein-to-creatinine ratio (UPCR) to detect lupus nephritis—proteinuria >0.5 g/24 hours or active urinary sediment (red blood cell casts, dysmorphic RBCs) warrants immediate nephrology referral. 2, 3, 1
• Antiphospholipid antibodies (lupus anticoagulant, anticardiolipin IgG/IgM, anti-β2-glycoprotein-I IgG/IgM) to assess thrombotic risk and pregnancy complications. 2, 4

Organ-Specific Evaluation

• For suspected lupus nephritis: Obtain renal biopsy to determine ISN/RPS class (III, IV, V), as histology independently predicts clinical outcome and guides immunosuppressive therapy. 2, 3, 1, 4
• For cutaneous manifestations: Evaluation by an experienced dermatologist and skin biopsy for histological analysis may be required, as many conditions mimic lupus. 2
• For neuropsychiatric symptoms (seizures, psychosis, acute confusional state, myelopathy): Perform comprehensive diagnostic workup including brain MRI, lumbar puncture (if safe), and exclude infection aggressively before attributing symptoms to lupus. 2, 3, 4

Disease Activity Monitoring

• Apply validated disease activity indices (SLEDAI-2K, BILAG, or SLE-DAS) at each visit to objectively quantify disease activity and detect flares. 2, 1, 4
• Use quantitative anti-dsDNA assays (preferably the same method and laboratory used at diagnosis) to monitor disease activity—rising titers sometimes correlate with active renal disease. 2, 1
• Anti-C1q antibodies have critical negative predictive value—lupus nephritis flares are unlikely in their absence. 2, 1
• Do not repeat ANA testing after initial positive result—it is not useful for monitoring disease activity. 1

---

Treatment Plan

All patients with SLE should immediately start hydroxychloroquine at ≤5 mg/kg real body weight combined with glucocorticoids tailored to disease severity, with the primary goal of achieving remission or low disease activity while minimizing chronic steroid exposure to <7.5 mg/day prednisone equivalent. 2, 3, 5, 6

Foundation Therapy (Mandatory for All Patients)

• Hydroxychloroquine is the cornerstone of therapy and must be prescribed to all patients unless contraindicated, as it reduces disease activity, prevents flares, improves survival, and reduces mortality. 2, 3, 1, 4, 5, 6
• Dose: ≤5 mg/kg of real body weight (generally 200–400 mg daily). 3, 1, 6
• Ophthalmological screening must be performed at baseline, after 5 years, then yearly thereafter using visual fields examination and/or spectral domain-optical coherence tomography to monitor for retinal toxicity. 3, 4, 6

Glucocorticoid Management Algorithm

• For severe/organ-threatening flares: Give intravenous methylprednisolone 250–1000 mg daily for 1–3 consecutive days as pulse therapy, followed by oral prednisone 0.3–0.5 mg/kg/day; this regimen provides rapid disease control while allowing lower oral steroid doses. 3, 6
• For mild-to-moderate flares: Start oral prednisone 0.5–1 mg/kg/day with taper over 2–4 weeks. 3
• Tapering goal: Reduce prednisone to ≤7.5 mg/day within 3–6 months of flare onset; maintaining higher doses markedly raises the risk of irreversible organ damage, infections, osteonecrosis, and mortality. 2, 3, 6
• Long-term maintenance: Target a dose of <5 mg/day and withdraw completely when possible. 3, 6

Immunosuppressive Therapy Selection

Prompt initiation of immunosuppressive agents is mandatory to control disease and facilitate glucocorticoid tapering/discontinuation. 3, 6

• Methotrexate (15–25 mg orally once weekly) is recommended for predominant cutaneous and articular manifestations. 3, 6
• Azathioprine (1–2.5 mg/kg/day) is recommended for maintenance therapy, particularly suitable for women contemplating pregnancy. 3, 6
• Mycophenolate mofetil (2–3 g/day divided doses) is recommended for renal and most non-renal manifestations (excluding neuropsychiatric disease). 3, 6
• Cyclophosphamide is reserved for severe organ-threatening or life-threatening SLE, especially renal, cardiopulmonary, or neuropsychiatric manifestations. 3, 6

Organ-Specific Treatment Protocols

Lupus Nephritis

• Induction therapy: Mycophenolate mofetil (2–3 g/day) or low-dose IV cyclophosphamide (500 mg every 2 weeks × 6 doses) combined with IV methylprednisolone pulse plus oral prednisone. 3, 6
• Add-on therapy: Consider belimumab or calcineurin inhibitors (voclosporin or tacrolimus) for enhanced efficacy. 6
• Maintenance therapy: Mycophenolate mofetil or azathioprine. 3, 6
• Response goal: Aim for at least partial remission (≥50% reduction in proteinuria to subnephrotic levels, creatinine within 10% of baseline) by 6–12 months. 3

Neuropsychiatric Lupus

• For inflammatory/immune-mediated mechanisms: High-dose IV methylprednisolone combined with cyclophosphamide. 3
• For thrombotic/embolic mechanisms: Initiate anticoagulation with warfarin (target INR 2.0–3.0 for first venous thrombosis; 3.0–4.0 for arterial or recurrent thrombosis). 3
• When both mechanisms coexist: Combination of immunosuppressive and anticoagulant therapy. 3

Severe Hematologic Manifestations

• For significant thrombocytopenia: High-dose glucocorticoids (including IV methylprednisolone pulses) combined with immunosuppressive agents (azathioprine, mycophenolate mofetil, or cyclosporine). 3
• IV immunoglobulin may be added in the acute phase or with inadequate response to glucocorticoids. 3
• For refractory cases: Rituximab or cyclophosphamide. 3

Cutaneous Manifestations

• First-line: Medium- to high-potency topical corticosteroids (triamcinolone or clobetasol) twice daily to affected areas; use low-potency hydrocortisone on facial lesions to avoid skin atrophy. 4
• Alternative: Topical calcineurin inhibitors (tacrolimus) for facial involvement. 4
• Systemic therapy: Hydroxychloroquine plus short-term systemic glucocorticoids for widespread or severe disease. 4
• Refractory cases: Add methotrexate, azathioprine, or mycophenolate mofetil; consider belimumab or rituximab for cases unresponsive to standard therapies. 4

Biologic Therapies for Refractory Disease

• Belimumab (anti-BAFF antibody) is recommended as add-on treatment for active extrarenal SLE and lupus nephritis in patients receiving standard therapy. 3, 5, 6
• Anifrolumab (anti-type 1 interferon receptor) is recommended for moderate-to-severe extrarenal SLE. 3, 5, 6
• Rituximab is recommended for organ-threatening disease refractory to or with intolerance/contraindications to standard immunosuppressive agents. 3, 6
• Voclosporin (novel calcineurin inhibitor) is approved for lupus nephritis in combination with standard of care. 3, 5

---

Essential Adjunctive Measures

• Photoprotection: Strict use of broad-spectrum sunscreen (SPF ≥50–60), avoidance of direct sunlight between 10 am and 4 pm, and wearing protective clothing and hats for all patients with cutaneous manifestations. 1, 4
• Low-dose aspirin (75–100 mg daily) for patients with antiphospholipid antibodies for primary prevention of thrombosis. 3, 1, 4
• Long-term anticoagulation with warfarin for patients with antiphospholipid-associated thrombosis. 3, 4
• Calcium (1000–1500 mg) plus vitamin D (800–1000 IU) daily for all patients receiving glucocorticoids to protect bone health. 3, 1
• Pneumocystis jirovecii prophylaxis (trimethoprim-sulfamethoxazole) if using high-dose glucocorticoids or multiple immunosuppressants. 1

---

Monitoring During Treatment

• Every 3 months for stable patients: Clinical examination, complete blood count, serum creatinine, urinalysis with microscopy, C3/C4 levels, and anti-dsDNA antibodies. 2, 1, 4
• Blood pressure at every visit, as hypertension predicts worse renal survival. 2, 1
• Screen aggressively for infections, cardiovascular disease, hypertension, diabetes, dyslipidemia, osteoporosis, avascular necrosis, and malignancies (especially non-Hodgkin lymphoma, lung cancer, hepatobiliary cancer)—SLE patients have a 5-fold increased mortality risk. 3, 4

---

Critical Pitfalls to Avoid

• Do not maintain chronic oral prednisone >7.5 mg/day, as this is the principal driver of steroid-related toxicity and damage accrual. 3, 6
• Do not delay initiation of immunosuppressive agents; early use is essential for enabling rapid steroid tapering. 3, 6
• Do not omit hydroxychloroquine—its continued use is critical for all patients regardless of flare status. 3, 5, 6
• Never assume fever is solely due to lupus activity without excluding infection first; do not escalate immunosuppression empirically for fever alone without comprehensive infectious workup. 4
• Do not attribute neuropsychiatric symptoms to lupus before aggressively excluding infection. 3, 4

---

Special Populations: Pregnancy

• Safe medications: Prednisolone, azathioprine, hydroxychloroquine, and low-dose aspirin. 3, 4
• Contraindicated medications: Mycophenolate mofetil, cyclophosphamide, and methotrexate must be avoided. 3, 4
• Preconception planning: Switch to pregnancy-compatible medications at least 3 months before conception; disease should be quiescent for a minimum of 6 months before attempting conception. 3
• Monitoring: Patients with lupus nephritis and antiphospholipid antibodies have higher risk of preeclampsia and require closer monitoring. 4